The US FDA has approved a Phase 2 compassionate care trial of Aviptadil by the US-Israeli biotech NeuroRx at Rambam Medical Center on coronavirus patients. Aviptadil combats coronavirus- triggered Acute Respiratory Distress Syndrome (ARDS) in the lungs, which is fatal in 50% of sufferers.